Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.

Frontiers in immunology - 1 Jan 2021

Shi Fuyan, Zhang Wenjing, Yang Yichen, Yang Yitao, Zhao Junyi, Xie Mengqi, Sheng Chao, Wang Suzhen, Wang Qinghua

Abstract excerpt

Background: Despite the acknowledged sex-related differences in immune response and immune checkpoint inhibitor (ICI) efficacy, little is known about the sex disparities in melanoma of novel genomic determinants for ICI therapies. Methods: Pretreatment genomic profiles and clinical characteristics of 631 melanoma patients treated with ICIs (i.e., inhibitors of CTLA-4, PD-1/PD-L1, or both) were comprehensively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Complement Factor H

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Sex Factors

Share to Survival Analysis

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 34795662
DOI: 10.3389/fimmu.2021.721409
PMCID: PMC8594267

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.PMID 34795662Read ↗

Sex-based mutational landscape confers sensitivity to checkpoint blockade immunotherapy in cutaneous melanomaSemantic proximity Read ↗

Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities.Semantic proximity Read ↗

Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients.Semantic proximity Read ↗

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.Semantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

Sex-specific differences in immunogenomic features of response to immune checkpoint blockadeSemantic proximity Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

Gender-Dependent Specificities in Cutaneous Melanoma Predisposition, Risk Factors, Somatic Mutations, Prognostic and Predictive Factors: A Systematic Review.Semantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Let’s talk about sex: A biological variable in immune response against melanomaSemantic proximity Read ↗

Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanomaSemantic proximity Read ↗

Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex biasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.